Under the agreement, Bionova will serve as the preferred manufacturing partner for Syenex’s best-in-class delivery platforms.

Hematopoietic stem cells (HSCs) are one of the most promising targets for gene therapy applications. Owing to their biological properties of self-renewal, multilineage differentiation and long-term ...

Processes yielding >500 mg plasmid DNA/L have previously been reported by Merck, Boehringer Ingelheim, and Nature Technology (NTC). Common features among these high-yield processes include the use of ...

DUBLIN--(BUSINESS WIRE)--The "Viral Vectors & Plasmid DNA Manufacturing Market Report 2024-2034" report has been added to ResearchAndMarkets.com's offering. Overall world revenue for the viral vectors ...